Merck will suspend the supply of HPV vaccine Gardasil to the Chinese market
February 6, 2025
Source: drugdu
32
On February 4, local time, Merck announced the suspension of the supply of HPV vaccine Gardasil to China, and the suspension is expected to last at least until the middle of the year. The financial report released by Merck on the same day showed that the company's fourth quarter sales were US$15.6 billion, a year-on-year increase of 7%, of which Gardasil sales fell 17% year-on-year to US$1.55 billion. Merck said the main reason was the reduction in demand in China.
In January this year, Merck's HPV vaccine Gardasil was approved for marketing by the National Medical Products Administration for multiple new indications, suitable for males aged 9 to 26, becoming the first and currently the only approved HPV vaccine for men in China.
https://finance.eastmoney.com/
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Haisike has been approved to conduct clinical trials of the innovative drug HSK39004 February 7, 2025
- Innovative drugs are expected to accelerate into hospitals, and the Class C medical insurance catalogue is about to be released February 7, 2025
- Keytruda sold $29.5 billion last year, and Merck suspended shipments of HPV vaccines to the Chinese market February 7, 2025
- The application for marketing authorization of the independently developed drug of the holding subsidiary was approved by the EU February 7, 2025
- Nepal launches national HPV vaccination program, expected to benefit more than 1.68 million girls February 6, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
